Drug intelligence / Profile preview

SA-003

Development stage: Preclinical
Lead developer: Samjin Pharmaceutical

Overview

SA-003 is an early-stage drug candidate currently under development by Sanopeutics for the treatment of infectious diseases. As of early 2024, the program is positioned in the discovery or preclinical screening phase. Due to limited public disclosure by the developer, specific information regarding the drug's molecular target, modality (such as small molecule or monoclonal antibody), and the specific infectious pathogens it is intended to target remains unavailable.

Beyond the preview

Go deeper on SA-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SA-003.

Explore the full profile